HCA
CLB icon

Harpswell Capital Advisors’s Core Laboratories CLB Stock Holding History

Harpswell Capital Advisors’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$113K Buy
11,700
+46
+0.4% +$532 0.07% 43
2026
Q2 		$136K Buy
+11,654
New +$166K 0.09% 46

Other funds holding CLB

FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Harpswell Capital Advisors's CLB Position: Q3 2026 in Review

Harpswell Capital Advisors increased its Core Laboratories (CLB) stake by 0.39% in Q3 2026, buying an estimated $532 and bringing the position to 11,700 shares worth $113K. The position accounts for 0.07% of the portfolio, ranked #43.

Harpswell Capital Advisors first reported a position in CLB in Q2 2026 and has held it in 2 quarters since. The position peaked at $136K in Q2 2026. 4 funds tracked by Wall St. Rank hold CLB as of Q3 2026.

  • Harpswell Capital Advisors held 11,700 shares of Core Laboratories worth $113K as of Q3 2026.
  • Harpswell Capital Advisors bought 46 Core Laboratories shares in Q3 2026, an estimated $532.
  • Core Laboratories made up 0.07% of Harpswell Capital Advisors's portfolio in Q3 2026, its #43 holding.
  • Harpswell Capital Advisors first reported a position in Core Laboratories in Q2 2026 and has held it in 2 quarters since.
  • Harpswell Capital Advisors's Core Laboratories position peaked at $136K in Q2 2026.
  • 4 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2026.

Based on Harpswell Capital Advisors's 13F filing for Q3 2026, filed 9 Oct 2026.